POST-TRANSPLANT IMMUNOTHERAPY WITH ALLOGENEIC DONOR-DERIVED CIK CELLS AFTER HLA-MISMATCHED TRANSPLANTATION (SIE 2026) - Oct 6, 2026 - Abstract #C092; Pres time: Sep 23, 2026; 02:15 PM - 03:45 PM; Location: HALL 3; P1/2 | "Donor-derived CIK cells after post-HCT re- lapse were feasible and safe in haploidentical and HLA-mis- matched settings, with promising activity, especially in MRD relapse or MC. These findings support earlier prophylactic evaluation of CIK cells in high risk patients after HCT."
Post-transplantation • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelofibrosis • Transplantation • CD8 • IFNG • IL2 • NCAM1
|
|
G. Rizzuto1,2; B. Rambaldi1; A. Algarotti1; G. Carioli3; A. Ghirardi3; E. Gotti145; S. Panna1,4,5; I. Cattaneo1,4,5; O. Pedrini1,3,5; R. Valgardsdottir1,4,5; C. Capelli1,4; L. Cantamessa1,4,6; Ml. Ferrari1,3; M. Paganessi1; A. Scannella1; F. Frenza1; G. Gritti1; S. Ferrari1; Mc. Finazzi1; A. Grassi1; Mc. Micò1; J. Golay4; M. Introna4; A. Rambaldi3; F. Lussana1,6
|